Molecular Pathology Laboratory Network
Molecular Pathology Laboratory Network is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
Sponsor Zydus Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Sponsor Agios Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Sponsor Acerta Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
Sponsor Fidia Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)
Sponsor Loxo Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL
Sponsor Italfarmaco S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor
Sponsor Abbisko Therapeutics Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Sponsor Loxo Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Sponsor Cellectar Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Molecular Pathology Laboratory Network?
The 2026-10-09 snapshot links Molecular Pathology Laboratory Network to 11 distinct CTIS trials. Recorded services include Laboratory services, BMA cytogenetics, cytomorphology, RNA and NGS testing and storage. BMB cytomorphology testing, Deletion 17p, IGHV, Complex karyotype Bone, Marrow Aspirate, MPN Mutation Panel Blood and IHC. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Molecular Pathology Laboratory Network?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Hepatology, Musculoskeletal. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Molecular Pathology Laboratory Network conducted?
The linked trials record locations in 20 countries, including France, Spain, Italy, Poland, Czechia. These are trial locations, not confirmed office locations or countries where Molecular Pathology Laboratory Network delivered services.
What can this page tell me about Molecular Pathology Laboratory Network's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Molecular Pathology Laboratory Network. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Molecular Pathology Laboratory Network Inc.